Upcoming Events
  1. TACT Board Teleconference (closed)

    August 28 - August 29
  2. ESMO 2017 Congress, Madrid Spain

    September 8 - September 12
  3. ***UPDATED*** 3rd ALTG Preceptorship in Lung Cancer, Melbourne VIC

    September 22 @ 12:00 pm - September 23 @ 5:00 pm UTC+10
  4. TACT General Assembly (closed), Yokohama Japan

    October 15
  5. 18th WCLC, Yokohama Japan

    October 15 - October 18

ALTG 10/001 PLUNG-GP: Randomised phase III trial of high dose palliative radiotherapy (HDPRT) vs concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/small volume metastatic NSCLC not suitable for radical chemo-radiotherapy – M Lehman

The PLUNG-GP trial is a randomized Phase III trial comparing high dose palliative radiotherapy (HDPRT) with concurrent chemotherapy + HDPRT (C-HDPRT) in patients with good performance status, locally advanced or small volume metastatic NSCLC who are not suitable for radical chemo-radiotherapy, either due to tumour extent or patient factors. The optimal treatment approach for this group of patients is unknown and clinical practice varies throughout Australia. The PLUNG trial compares a widely employed high dose palliative radiotherapy regime (36Gy/12F) with a concurrent chemotherapy and high dose palliative radiotherapy regime (40Gy/20F + Vinorelbine + Cisplatin) which has been investigated in preceding Phase I and II trials conducted under the auspices of the Trans Tasman Radiation Oncology Group (TROG).

The objectives of the trial are to determine which regime is superior in terms of symptom relief and improvement in quality of life. The study aims to recruit 130 patients and has recently received a three year extension of funding from Cancer Australia. The study is open at PAH, Peter MacCallum Cancer Centre, Townsville, Royal Brisbane, Calvary Mater Newcastle, Flinders Medical Centre, Allan Walker Centre Darwin, Liverpool, ROQ Gold Coast Hospital, Cairns and St George Hospital with recruitment now at 59 patients.

For anyone who is interested in this study please contact either Dr Margot Lehman margot.lehman@health.qld.gov.au or A/Prof Michael Michael michael.michael@petermac.org